Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 2/20 | 0.32 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.31 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5260623 | 0.75 | PDE10A (0.33) | — | |
| SCHEMBL28393579 | 0.74 | MAPT (0.36) | NPY5R | |
| SCHEMBL3644139 | 0.74 | NPY5R (0.31) | NPY5R | |
| SCHEMBL423879 | 0.74 | MASP2 (0.48) | CDK5CDK5R1NPY5R | |
| SCHEMBL127415 | 0.74 | MAPT (0.36) | NPY5R | |
| SCHEMBL129499 | 0.74 | NPY5R (0.31) | NPY5R | |
| SCHEMBL3858640 | 0.74 | CYP2A6 (0.47) | NPY5R | |
| SCHEMBL29882567 | 0.74 | — | — | |
| SCHEMBL15820238 | 0.72 | KDM4C (0.38) | — | |
| SCHEMBL7245878 | 0.71 | PDE10A (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110950806-A | Preparation method of pyrimidine cyclic hydroxy chloride by catalysis of tetraethylammonium chloride | 安庆博曼生物技术有限公司 | 2020-04-03 | — | — | CN | claimed |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-10899765-B2 | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation | CHEMOCENTRYX, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| CN-111454261-A | Synthesis method of 4-chloro-pyrrolopyrimidine compound | 南京普锐达医药科技有限公司 | 2020-07-28 | — | — | CN | disclosed |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2020-05-14 | — | — | US | disclosed |
| CN-110950806-A | Preparation method of pyrimidine cyclic hydroxy chloride by catalysis of tetraethylammonium chloride | 安庆博曼生物技术有限公司 | 2020-04-03 | — | — | CN | disclosed |
| US-20190167651-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20190169197-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CHEMOCENTRYX, INC. | 2019-06-06 | — | — | US | disclosed |
| US-10206912-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-10208050-B2 | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation | CHEMOCENTRYX, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| CN-101820881-B | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treament of inflammation | CHEMOCENTRYX | 2013-05-01 | — | — | CN | disclosed |
| EP-2175859-B1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESULFONAMIDES AS CCR2 MODULATORS FOR THE TREAMENT OF INFLAMMATION | CHEMOCENTRYX INC (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20110319433-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CHEMOCENTRYX, INC. | 2011-12-29 | — | — | US | disclosed |
| US-20110118248-A1 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2011-05-19 | — | — | US | disclosed |
| US-7884110-B2 | 4-Chloro-N-[5-methyl-2-(7H-pyrrolo[2,3-d]pyrimidine-4-carbonyl)-pyridin-3-yl]-3-trifluoromethyl-benzenesulfonamide sodium salt; for chemokine-mediated conditions or diseases including certain inflammatory and immunoregulatory disorders; restenosis, multiple sclerosis, arthritis | CHEMOCENTRYX, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| CN-101820881-A | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as ccr2 modulators for the treament of inflammation | CHEMOCENTRYX INC | 2010-09-01 | — | — | CN | disclosed |
| EP-2175859-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESULFONAMIDES AS CCR2 MODULATORS FOR THE TREAMENT OF INFLAMMATION | ChemoCentryx Inc (US) | 2010-04-21 | — | — | EP | disclosed |
| US-20090233946-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CHEMOCENTRYX, INC. | 2009-09-17 | — | — | US | disclosed |
| WO-2009009740-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREAMENT OF INFLAMMATION | CHEMOCENTRYX, INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| WO-2008008431-A2 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | CDK5 878/4885CDK5R1 506/4885NPY5R 2330/4885 |
| US-10899765-B2 | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation | CCR2, CXCR2, CX3CR1 | CDK5 657/4885CDK5R1 366/4885NPY5R 1610/4885 |
| US-10206912-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | CDK5 878/4885CDK5R1 506/4885NPY5R 2330/4885 |
| US-20190169197-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CCR2, CXCR2, CX3CR1 | CDK5 657/4885CDK5R1 366/4885NPY5R 1610/4885 |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | CDK5 878/4885CDK5R1 506/4885NPY5R 2330/4885 |
| US-20110118248-A1 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | CDK5 878/4885CDK5R1 506/4885NPY5R 2330/4885 |
| US-10208050-B2 | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation | CCR2, CXCR2, CX3CR1 | CDK5 657/4885CDK5R1 366/4885NPY5R 1610/4885 |
| US-20090233946-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CCR2, CXCR2, CX3CR1 | CDK5 657/4885CDK5R1 366/4885NPY5R 1610/4885 |
| US-20190167651-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CCR2, CCR9, CCR1 | CDK5 878/4885CDK5R1 506/4885NPY5R 2330/4885 |
| US-20110319433-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CCR2, CXCR2, CX3CR1 | CDK5 657/4885CDK5R1 366/4885NPY5R 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.